## S3 Table. Clinical information of patients

| Tissue ID | Histological type | Age | Clinicopathologic stage | Follow-up time OS | $\begin{gathered} \text { OS }(0=\text { survival, } \\ 1=\text { death }) \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 201101623 | HGSC, OV | 56 | III | 50 | 0 |
| 201105937 | HGSC, bilateral HGSC-OV | 43 | IIIc | 48 | 0 |
| 201106046 | HGSC, HGSC on the surface and in the omentum of bilateral ovary | 60 | IV | 1 | 1 |
| 201110256 | HGSC, HGSC infiltration in bilateral ovary | 54 | IIIc | 42 | 1 |
| 201115028 | HGSC, HGSC in right ovary | 68 | IIIc | 15 | 0 |
| 201119151 | CCC, CCC in bilateral ovary | 59 | I | 40.5 | 0 |
| 201119229 | HGSC in bilateral ovary with features of urothelium carcinoma | 56 | IIIc | 40.5 | 0 |
| 201119290 | HGSC-bilateral ovary | 46 | IIb | 18 | 0 |
| F201100037 | HGSC, OV | 55 | IIIc | 51 | 0 |
| F201100235 | HGSC, OV | 49 | IIIc | 6 | 0 |
| F201100402 | HGSC, OV | 76 | IIIc | 29 | 1 |
| F201100409 | HGSC, OV | 43 | IIB | 49 | 0 |
| F201100608 | HGSC, OV | 62 | IIIc | 37 | 1 |
| F201100609 | MC, Borderline Mucinous Ovarian Tumors in left ovary with focal intraepithelial carcinoma and small infiltration in stromal | 67 | Ic | 48 | 0 |
| F201100708 | HGSC, bilateral HGSC-OV, undifferentiated carcinoma seen in some area | 75 | IIIc | 48 | 0 |
| F201100778 | MC with necrosis, medium-high differentiation | 57 | IIIb | 7 | 0 |
| F201100838 | MC, OV, medium-high differentiation; primary cancer from endometrium and ovary | 49 | $\begin{aligned} & \text { I (ovarian), II } \\ & \text { (endometrial) } \end{aligned}$ | 47 | 0 |
| F201100854 | HGSC, bilateral HGSC-OV | 58 | IIIc | 47 | 0 |
| F201100997 | EC, OV, middle-differentiated endometroid adenocarcinoma with differentiating squamous carcinoma | 45 | $\begin{gathered} \text { Ia (Ovarian), IIIa } \\ \text { (endometrial) } \end{gathered}$ | 46 | 0 |


| F201101097 | HGSC, HGSC-OV in bilateral ovary | 52 | III | 6 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| F201101371 | HGSC, HGSC in ovary and oviduct | 66 | IIIc | 1 | 1 |
| F201101435 | HGSC, HGSC in left ovary | 49 | IV | 44.5 | 0 |
| F201101447 | HGSC, bilateral HGSC-OV | 48 | III | 44 | 0 |
| F201101471 | HGSC and MC, serous-mucinous papillary cystadenocarcinoma in ovary | 49 | Ic | 44.5 | 0 |
| F201101557 | Poor-differentiated adenocarcinoma, unclassified | 60 | I | 43.5 | 0 |
| F201101619 | HGSC, bilateral HGSC-OV with differentiating to DNES | 44 | IV | 15 | 0 |
| F201101744 | CCC, Ovarian CCC | 43 | IA | 42.5 | 0 |
| F201101811 | MC | 24 | IA | 42.5 | 0 |
| F201101855 | HGSC, HGSC in bilateral ovary | 59 | IIIc | 42 | 0 |
| F201101955 | HGSC, HGSC in right ovary | 57 | II | 42 | 0 |
| F201101978 | HGSC | 46 | IIIc | 41.5 | 0 |
| F201102044 | bilateral ovarian malignant mixed Müllerian tumor, epithelial component is mostly high-grade serous adenocarcinoma with focal differentiating area to smooth muscle | 60 | IIIc |  |  |
| F201102072 | MC, borderline mucinous ovarian tumors in right ovary with cancerization in some area (middledifferentiated adenocarcinoma), with necrosis | 62 | IA | 41.5 | 0 |
| F201102276 | MC , borderline serum-mucinous papillary cystadenocarcinoma with cancerization in some area (highlydifferentiated serum adenocarcinoma) | 88 | IA | 40.5 | 0 |
| F201102338 | Bilateral ovarian low-differentiated adenocarcinoma with formation of psammoma bodies | 59 | III | 5 | 0 |
| F201102418 | bilateral ovarian HGSC | 49 | IIIc | 16 | 1 |
| F201102421 | HGSC in left ovary | 49 | IA | 39.5 | 0 |
| 201201355 | HGSC, bilateral ovarian serum adenocarcinoma, middle-low differentiated | 75 | IV | 38.5 | 0 |
| 201202790 | HGSC, serum adenocarcinoma in bilateral ovary, middle-low differentiated | 63 | IIIC | 38 | 0 |
| 201203563 | HGSC, high-grade serum adenocarcinoma | 62 | III | 38 | 0 |
| 201205042 | HGSC, bilateral ovarian serum adenocarcinoma | 63 | IIIc | 36.5 | 0 |
| 201213058 | HGSC, high-grade serum adenocarcinoma in bilateral accessories | 73 | IIIc | 21 | 1 |


| 201213290 | HGSC, middle-differentiated serum adenocarcinoma in ovary | 74 | IIIc | 32 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 201216274 | Low-differentiated adenocarcinoma, Possible low-differentiated serum adenocarcinoma | 33 | IV | 3 | 0 |
| 201219112 | high-differentiated MC | 56 | IIIb | 10 | 1 |
| 201220145 | HGSC | 57 | IIIc | 19 | 1 |
| 201220245 | HGSC | 50 | IIIb | 5 | 0 |
| 201221870 | HGSC | 64 | IIIc | 27.5 | 0 |
| F201200194 | HGSC | 79 | III | 13 | 1 |
| F201200243 | HGSC, low-differentiated serum adenocarcinoma in right ovary | 57 | IIIB | 38 | 0 |
| F201200481 | MC | 42 | Ia | 36.5 | 0 |
| F201200520 | HGSC, middle-differentiated serum papillary cystadenocarcinoma | 58 | IIc | 36.5 | 0 |
| F201200588 | MC | 59 | Ic | 4 | 0 |
| F201200783 | MC | 20 | Ic | 5 | 0 |
| F201200871 | CCC | 57 | Ic | 30 | 1 |
| F201201001 | HGSC, low-differentiated serum adenocarcinoma in right ovary | 75 | IIIc | 34.5 | 0 |
| F201201007 | CCC | 50 | IV | 34.5 | 0 |
| F201201164 | HGSC, medium-differentiated serum adenocarcinoma in bilateral ovary | 59 | IIIc | 5 | 0 |
| F201201187 | HGSC, bilateral ovarian serum adenocarcinoma, middle-differentiated | 63 | IIIc | 17 | 1 |
| F201201303 | bilateral ovarian HGSC | 60 | IIIc | 33 | 0 |
| F201201531 | HGSC, high-grade serum adenocarcinoma in bilateral ovary | 56 | IIIc | 32 | 0 |
| F201201648 | HGSC and MC, borderline serum-mucinous papillary cystadenocarcinoma with cancerization components of HGSC and high- differentiated MC | 57 | IIIC | 31.5 | 0 |
| F201201734 | HGSC | 60 | IIIC | 20.5 | 1 |
| F201201746, | HGSC in right ovary | 42 | IIIc | 24 | 0 |
| F201201764 | HGSC+EC | 60 | Ic | 31 | 0 |
| F201201896 | HGSC | 50 | IIIc | 30 | 0 |
| F201201939 | Borderline serum-endometria cystadenocarcinoma | 38 | Ic | 30 | 0 |


| F201201945 | HGSC | 60 | Ia | 31 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| F201201960 | MC with large area of necrosis | 26 | Ia | 6 | 0 |
| F201202102 | CCC | 61 | IIIc | 13.5 | 1 |
| F201202118 | HGSC | 50 | IV | 30.5 | 0 |
| F201202185 | HGSC | 57 | IIIC | 1 | 1 |
| F201202250 | HGSC in bilateral ovary | 61 | IIIb | 21 | 1 |
| F201202306 | HGSC in bilateral ovary | 54 | IIIc | 16 | 1 |
| 201300556 | HGSC, with carcinoma tissue mostly on the surface | 54 | III | 5 | 0 |
| 201304123 | HGSC | 61 | IIIC | 26.5 | 0 |
| 201307816 | Middle-differentiated papillary HGSC | 80 | IIIc | 26.5 | 0 |
| 201308398 | HGSC | 65 | IIIc | 26 | 0 |
| 201312221 | MC | 33 | IA | 12.5 | 0 |
| 201314100 | Undifferentiated carcinoma, differentiating to neuroendocrine cell in left ovary | 63 | IV | 25 | 0 |
| 201314640 | Mixed MC-EC, middle-differentiated | 66 | Ia | 16 | 1 |
| 201320209 | CCC | 51 | Ic | 22.5 | 0 |
| 201324435 | HGSC on surface of bilateral ovary | 54 | IIIC | 17 | 0 |
| 201326852 | HGSC, pelvic disseminated, endometrial small tumor, widespread cancer embolus in vessels | 51 | IIIC | 22 | 0 |
| 201327702 | HGSC | 62 | IIIc | 21.5 | 0 |
| 201333411 | CCC with necrosis | 52 | Ic | 20.5 | 0 |
| 201336443 | LGSC | 26 | IIIC | 18 | 1 |
| 201338595 | LGMPSC and HGSC | 56 | IIIc | 19 | 0 |
| 201340182 | HGSC | 60 | IIIc | 19 | 0 |
| 201342659 | HGSC | 57 | IIIC | 18.5 | 0 |
| 201343137 | HGSC | 62 | III | 18 | 0 |
| 201343346 | EC with differentiating to squamous carcinoma | 26 | Ic | 18 | 0 |
| 201345530 | HGSC | 46 | IIIc or IV | 1 | 1 |


| 201346512 | Borderline endometroid carcinoma with focal poor-differentiated adenocarcinoma | 29 | Ic | 17.5 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 201351349 | HGSC | 58 | IIIc | 17 | 0 |
| 201352444 | HGSC | 64 | III | 17 | 0 |
| 201355862 | HGSC | 50 | III | 17 | 0 |
| 201357039 | HGSC | 57 | IIIc | 16 | 0 |
| F201300419 | CCC | 50 | Ic | 6 | 0 |
| F201300502 | Low-differentiated adenocarcinoma and HGSC | 45 | IV | 1 | 1 |
| F201300523 | LGSC | 50 | IIIc | 24.5 | 0 |
| F201300684 | CCC | 61 | Ia | 5 | 0 |
| F201300710 | CCC | 49 | Ia | 23.5 | 0 |
| F201300762 | LGSC | 36 | Ia | 1 | 0 |
| F201300768 | EC, highly-differentiated | 55 | II | 23.5 | 0 |
| F201301035 | CCC | 63 | Ia | 7 | 0 |
| F201301058 | HGSC+CCC | 67 | IIIc | 20.5 | 0 |
| F201301126 | HGSC | 68 | IIIC | 14 | 1 |
| F201301222 | MC, highly-differentiated | 41 | Ic | 22 | 0 |
| F201301327, | HGSC in bilateral ovary with chemotherapy reaction, after the second chemotherapy | 65 | above IIc | 2 | 0 |
| F201301618 | EC, highly-differentiated | 56 | Ic | 1 | 1 |
| F201301748 | MC | 18 | Ia | 20 | 0 |
| F201301758 | EC | 50 | Ic | 5 | 0 |
| F201301968 | HGSC | 74 | IIb | 19.5 | 0 |
| F201302436 | Highly-differentiated EC | 76 | Ia | 18 | 0 |
| F201302595 | Highly-differentiated MC | 57 | IIb | 17 | 0 |
| F201302618 | Highly-differentiated MC | 27 | IIc | 17.5 | 0 |
| F201302644 | HGSC | 66 | IIa | 17 | 0 |
| F201302659 | HGSC | 42 | IIIc | 17 | 0 |


| F201302842 | HGSC | 43 | IIIc | 16 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| F201302894 | HGSC | 52 | Ia | 17 | 0 |
| F201302895 | HGSC | 52 | IIIc | 15.5 | 0 |
| 201401943 | HGSC | 68 | IIIc | 15.5 | 0 |
| 201402163 | HGSC | 50 | IIIc | 15 | 0 |
| 201404067 | HGSC | 52 | IIIc | 14.5 | 0 |
| 201406454 | HGSC | 50 | IIIc | 14 | 0 |
| 201406455 | malignant mesodermal mixed tumors, $80 \%$ : HGSC | 72 | IIIc | 14 | 0 |
| 201406734 | HGSC | 52 | IIIc | 14 | 0 |
| 201407231 | HGSC | 58 | IIIc | 14 | 0 |
| 201411232 | HGSC | 55 | IIc | 5 | 0 |
| 201412772 | HGSC | 75 | IIIc | 13 | 0 |
| 201421680 | LGSC | 31 | I | 12 | 0 |
| 201421681 | HGSC | 63 | IIc | 5 | 0 |
| 201421949 | Low-differentiated EC | 50 | IIIc | 11 | 0 |
| 201429690 | HGSC | 68 | IIIc | 10 | 0 |
| 201431508 | EC | 84 | Ic | 10 | 0 |
| 201433629 | HGSC | 52 | IIIc | 9.5 | 0 |
| 201437476 | HGSC | 42 | IIIc | 9 | 0 |
| 201438226 | HGSC | 47 | IIIc | 8.5 | 0 |
| 201438514 | HGSC | 51 | IIIc | 8.5 | 0 |
| F201400223 | HGSC | 52 | III | 7 | 0 |
| F201400235 | MC | 59 | IA | 4 | 0 |
| F201400276, | HGSC | 52 | IIc | 15 | 0 |
| F201400570 | MC, High-Middle differentiated | 57 | Ia | 3 | 0 |
| F201400580 | EC, High-Middle differentiated | 39 | Ic | 6 | 0 |


| F201400740 | HGSC | 49 | IIIc | 12.5 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| F201401155 | Undifferentiated carcinoma | 32 | IIIC | 4 | 1 |
| F201401246 | LGSC | 39 | IV | 11 | 0 |
| F201401478 | MC | 26 | Ia | 10 | 0 |
| F201401559 | High-grade adenocarcinoma (HGSC) | 59 | Ia | 9.5 | 0 |
| F201401941 | MC, middle-differentiated | 72 | Ia | 8.5 | 0 |
| F201401970 | Low-grade EC in ovary | 50 | IIc | 8.5 | 0 |
| F201402010 | CCC | 39 | Ia | 8 | 0 |
| F201402044 | HGSC | 55 | Ia | 8 | 0 |
| F201402156 | LGSC | 78 | IIIB | 7 | 0 |
| 201219284 | CCC, after the second chemotherapy | 58 | IIIc | 24 | 1 |
| 201418290 | Low-differentiated ovarian adenocarcinoma, degree II c , after the 4th chemotherapy | 62 | IIIc | 5 | 0 |
| 201412597 | HGSC, after the 1st chemotherapy | 68 | IIIc | 1 | 1 |
| F201400554 | High-grade serum adenocarcinoma in left ovary; after the 3rd chemotherapy | 59 | IIIc | 4 | 0 |
| 201354791 | Bilateral ovarian high-grade serum adenocarcinoma; after the 3rd chemotherapy | 62 | IIIc | 5.5 | 0 |
| 201345063 | Bilateral ovarian high-grade HGSC with chemotherapy reaction, after the 2nd chemotherapy | 70 | IIIc | 14 | 0 |
| 201329725 | Bilateral ovarian high-grade serum adenocarcinoma; after the 2nd chemotherapy | 57 | IIIc | 2 | 0 |
| 201327524 | Left ovarian high-grade serum adenocarcinoma; after the 2nd chemotherapy | 69 | IIIc | 15 | 0 |
| 201314112 | Bilateral ovarian HGSC, after the 1st chemotherapy | 44 | IIIc | 7 | 0 |
| 201309323 | Left ovarian HGSC, after the 1st chemotherapy | 44 | IIIc | 5 | 0 |
| 201206761 | Serum adenocarcinoma, middle-low differentiated, after chemotherapy | 42 | IIIc | 7 | 0 |
| 201216808 | Bilateral high-grade serum adenocarcinoma with differentiating to neuroendocrine cell, after the 6th chemotherapy | 55 | IV | 27 | 0 |
| 201106664 | Bilateral ovarian low-differentiated adenocarcinoma, tending to CCC, after the 3rd chemotherapy | 62 | IIIc | 36 | 0 |
| 201103744 | Low-differentiated adenocarcinoma with chemotherapy reaction, after chemotherapy | 51 | IV | 18 | 0 |
| 201356775 | HGSC with light chemotherapy reaction (Low effect of chemotherapy reaction) | 46 | IIIc | 19 | 0 |


| 201342168 | CCC with light chemotherapy reaction | 59 | IIc | 9 | 0 |
| :--- | :--- | :--- | :--- | :---: | :---: |
| $\mathbf{2 0 1 1 1 6 6 9 1}$ | HGSC, bilateral ovarian HGSC-OV | 44 | III | 5 | 0 |
| $\mathbf{2 0 1 1 1 5 5 1 7}$ | HGSC | 53 | IIIc | 43.5 | 0 |
| F201101596 | HGSC, bilateral ovarian HGSC | 57 | IIIc | 14 | 0 |

OS, overall survival; HGSC, high-grade serous carcinomas; OV, ovarian; CCC, clear cell carcinomas; MC, mucinous carcinomas; EC, endometrioid adenocarcinoma; DNES, diffuse neuroendocrine system; LGSC, low-grade serous carcinomas; LGMPSC, low-grade micropapillary serous carcinomas.

